{"Symbol": "BMY", "AssetType": "Common Stock", "Name": "Bristol-Myers Squibb Company", "Description": "Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.", "CIK": "14272", "Exchange": "NYSE", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "DRUG MANUFACTURERS - GENERAL", "Address": "ROUTE 206 & PROVINCE LINE ROAD, PRINCETON, NJ, UNITED STATES, 08543", "OfficialSite": "https://www.bms.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-12-31", "MarketCapitalization": "123695415000", "EBITDA": "19115999000", "PERatio": "17.55", "PEGRatio": "2.256", "BookValue": "9.07", "DividendPerShare": "2.49", "DividendYield": "0.0416", "EPS": "3.46", "RevenuePerShareTTM": "23.69", "ProfitMargin": "0.146", "OperatingMarginTTM": "0.282", "ReturnOnAssetsTTM": "0.103", "ReturnOnEquityTTM": "0.404", "RevenueTTM": "48193999000", "GrossProfitTTM": "35000001000", "DilutedEPSTTM": "3.46", "QuarterlyEarningsGrowthYOY": "13.92", "QuarterlyRevenueGrowthYOY": "0.013", "AnalystTargetPrice": "59.91", "AnalystRatingStrongBuy": "3", "AnalystRatingBuy": "6", "AnalystRatingHold": "17", "AnalystRatingSell": "1", "AnalystRatingStrongSell": "0", "TrailingPE": "17.55", "ForwardPE": "9.96", "PriceToSalesRatioTTM": "2.567", "PriceToBookRatio": "6.7", "EVToRevenue": "3.323", "EVToEBITDA": "10.52", "Beta": "0.295", "52WeekHigh": "62.05", "52WeekLow": "41.88", "50DayMovingAverage": "55.16", "200DayMovingAverage": "48.85", "SharesOutstanding": "2036474000", "SharesFloat": "2033195000", "PercentInsiders": "0.101", "PercentInstitutions": "83.179", "DividendDate": "2026-02-02", "ExDividendDate": "2026-01-02"}